CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-19 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $7.24 | $362K | 100,322 |
| 2024-07-18 | Morisset Valerie EVP, R&D AND CSO | Sale | −38,576 | $6.93 | $267K | 160,523 |
| 2024-07-17 | Morisset Valerie EVP, R&D AND CSO | Sale | −3,207 | $6.91 | $22K | 199,099 |
| 2024-07-16 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $7.13 | $357K | 202,306 |
| 2024-07-15 | Morisset Valerie EVP, R&D AND CSO | Sale | −42,377 | $7.01 | $297K | 252,306 |
| 2024-07-12 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $7.07 | $354K | 294,683 |
| 2024-07-11 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $7.11 | $356K | 344,683 |
| 2024-07-10 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $6.83 | $342K | 394,683 |
| 2024-07-09 | Morisset Valerie EVP, R&D AND CSO | Sale | −5,931 | $6.66 | $40K | 444,683 |
| 2024-07-05 | Morisset Valerie EVP, R&D AND CSO | Sale | −12,342 | $7.06 | $87K | 450,614 |
| 2024-07-03 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $6.76 | $338K | 462,956 |
| 2024-07-01 | Morisset Valerie EVP, R&D AND CSO | Option exercise | +7,649 | $0.00 | $2 | 512,956 |
| 2024-07-01 | Morisset Valerie EVP, R&D AND CSO | Option exercise · Stock Option (Right to Buy) | −7,649 | 10,198 | ||
| 2024-06-27 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +973,000 | 11,572,586 | ||
| 2024-06-27 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +2,479,872 | 2,479,872 | ||
| 2024-06-27 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +1,807,000 | 1,807,000 | ||
| 2024-06-27 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +11,949,171 | $3.84 | $45.9M | 23,521,757 |
| 2024-06-27 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +1,059,375 | $3.84 | $4.1M | 2,866,375 |
| 2024-06-27 | Brennan Aoife President and CEO | Grant or award · Stock Option (Right to Buy) | +550,000 | 550,000 | ||
| 2024-06-27 | Brennan Aoife President and CEO | Grant or award · Restricted Stock Units | +275,000 | 275,000 |
Page 5 of 9 · 166 trades